Related references
Note: Only part of the references are listed.FABP4 is Secreted from Adipocytes by Adenyl Cyclase-PKA- and Guanylyl Cyclase-PKG-Dependent Lipolytic Mechanisms
Tomohiro Mita et al.
OBESITY (2015)
Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population
Takahiro Fuseya et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy
Hideaki Yoshida et al.
HYPERTENSION RESEARCH (2014)
Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity
Arif U. Hasan et al.
HYPERTENSION RESEARCH (2014)
Adipocyte Lipid Chaperone aP2 Is a Secreted Adipokine Regulating Hepatic Glucose Production
Haiming Cao et al.
CELL METABOLISM (2013)
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials
Hisato Takagi et al.
HYPERTENSION RESEARCH (2013)
Circulating Levels of Fatty Acid-Binding Protein Family and Metabolic Phenotype in the General Population
Shutaro Ishimura et al.
PLOS ONE (2013)
Elevation of Fatty Acid-Binding Protein 4 Is Predisposed by Family History of Hypertension and Contributes to Blood Pressure Elevation
Hideki Ota et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease A 10-year Prospective Study
Maximilian von Eynatten et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Effects of Olmesartan, an Angiotensin II Receptor Blocker, on Peripheral Insulin Sensitivity in Japanese Subjects with Type 2 Diabetes and Hypertension
Seiya Shimoda et al.
INTERNAL MEDICINE (2012)
Valsartan Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism A randomized controlled trial
Nynke J. van der Zijl et al.
DIABETES CARE (2011)
Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients
Toru Miyoshi et al.
HEART AND VESSELS (2011)
Serum Fatty Acid-Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease
Masato Furuhashi et al.
PLOS ONE (2011)
Lipid Chaperones and Metabolic Inflammation
Masato Furuhashi et al.
INTERNATIONAL JOURNAL OF INFLAMMATION (2011)
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Seiichi Matsuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Adipocyte Fatty Acid-Binding Protein Suppresses Cardiomyocyte Contraction A New Link Between Obesity and Heart Disease
Valeria Lamounier-Zepter et al.
CIRCULATION RESEARCH (2009)
Comparative Effects of Telmisartan and Eprosartan on Insulin Sensitivity in the Treatment of Overweight Hypertensive Patients
R. Fogari et al.
HORMONE AND METABOLIC RESEARCH (2009)
Lipolysis and lipid mobilization in human adipose tissue
Max Lafontan et al.
PROGRESS IN LIPID RESEARCH (2009)
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Masato Furuhashi et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis
D. C. Y. Yeung et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2
Masato Furuhashi et al.
NATURE (2007)
Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome - A 5-year prospective study
Aimin Xu et al.
CIRCULATION (2007)
Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis
William J. Elliott et al.
LANCET (2007)
Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome
AM Xu et al.
CLINICAL CHEMISTRY (2006)
Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity
M Furuhashi et al.
JOURNAL OF HYPERTENSION (2004)
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-α activity
M Schupp et al.
CIRCULATION (2004)
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
SC Benson et al.
HYPERTENSION (2004)
Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension
M Furuhashi et al.
HYPERTENSION (2003)
Angiotensin blockade prevents type 2 diabetes by formation of fat cells
AM Sharma et al.
HYPERTENSION (2002)
Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis
L Makowski et al.
NATURE MEDICINE (2001)
Share Paper
